猪树突状细胞CD205纳米抗体介导FMDV抗原靶向提呈及其效应机制
批准号:
32102690
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
程海卫
依托单位:
学科分类:
兽医免疫学
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
程海卫
中文摘要
猪口蹄疫(FMD)疫苗在口蹄疫防控中发挥着重要作用,但仍存在抗原用量较大、不能诱导有效的细胞免疫等不足。CD205作为树突状细胞(DC)特异性的抗原提呈受体,抗原经CD205靶向后,可以诱导高效的免疫应答,在抗病毒感染和肿瘤治疗方面展现了良好的应用前景。CD205靶向在兽医领域研究日益受到关注,但其效应机制尚不清楚。本研究通过构建猪CD205/FMDV双特异纳米抗体实现FMDV抗原的CD205靶向,分别进行体内试验与体外试验,结合对抗原的不同处理,阐明CD205介导FMDV抗原靶向提呈的动力学过程、DC活化成熟、体液免疫及细胞免疫效应,并结合对DC蛋白质代谢的不同抑制剂处理以及CD4+T细胞、CD8+T细胞阻断试验,解析CD205介导FMDV抗原靶向提呈的效应机制。本研究不仅有助于设计针对猪CD205的新型、高效、主动靶向抗原输送系统,而且将对新型FMD疫苗设计提供思路和参考。
英文摘要
Pig foot-and-mouth disease vaccine plays an important role in the prevention and control of foot-and-mouth disease, but still has some shortcomings, such as large amount of antigen and inability to induce effective cellular immunity. CD205 is a specific antigen presenting molecule of dendritic cells, efficient immunity could be improved by targeting to CD205, which had a good application prospect during antiviral infection and oncotherapy. CD205 targeting has attracted increasing attention in the field of veterinary research, while its effect mechanism was still unclear. In this study, CD205 targeting of FMDV antigen was achieved by constructing a anti-pig CD205/FMDV bispecific-nanobody. In vitro and in vivo experiments were carried out, respectively, the dynamic process of CD205-mediated FMDV antigen targeting presentation, DC activation and maturation, humoral immunity and cellular immunity effects were clarified combined with different treatment of antigen. The mechanism of CD205-mediated FMDV antigen targeting presentation was analyzed in combination with different inhibitor treatments of DC protein metabolism and CD4+T cell and CD8+T cell blocking tests. This study would not only contribute to the design of a novel, efficient and actively antigen targeted delivery system for pig CD205, but also provide ideas and references for the design of novel FMD vaccines.
树突状细胞(DC)是功能强大的抗原提呈细胞,在诱导抗病毒免疫中起关键作用。本研究针对猪口蹄疫(FMD)疫苗免疫效力不足的问题,系统探索了CD205靶向策略在FMD疫苗研发中的应用潜力。通过构建猪CD205/FMDV双特异纳米抗体,以全病毒灭活抗原代替传统蛋白质抗原,实现了FMDV全病毒抗原的CD205靶向递送,并结合体内及体外实验阐明其免疫效应机制。研究结果显示,CD205靶向能够显著提升DC对FMDV全病毒抗原的摄取和提呈效率。与对照组相比,CD205/FMDV双特异纳米抗体试验组Nb4-Nb205显著促进BMDC成熟,靶向抗原优先通过CD205介导的内吞作用进入溶酶体,并在溶酶体中大量聚集,长达120分钟。经溶酶体加工后,抗原与MHC分子结合并呈递至T细胞,触发强劲的免疫应答。动物实验结果表明,CD205靶向处理可以诱导高水平液相阻断抗体生成,并同时增强Th1型和Th2型免疫反应,从而改善体液免疫和细胞免疫的协同效应,显著提高了FMD疫苗的免疫效力。此外,抑制剂(leupeptin、chloroquine或lactacystin)处理实验结果表明,溶酶体或蛋白酶体抑制能够干扰抗原的加工与提呈路径,抑制T细胞活性。同时,T细胞阻断实验结果显示,CD205靶向处理可以提升了IFN-γ和IL-4的分泌,而IL-17和TGF-β的水平差异不显著,说明CD205靶向递送倾向于增强细胞介导的免疫应答。综上所述,本研究表明基于CD205靶向的纳米抗体策略显著提升了FMDV抗原的免疫效力,尤其在细胞免疫方面表现出独特优势,为FMD疫苗的设计和优化提供了重要的理论依据与技术支持。同时,本研究为构建高效、主动靶向的抗原递送系统提供了新策略,为其他动物传染病疫苗的研发提供了参考。
国内基金
海外基金